Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement.

Trial Profile

Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Enoxaparin sodium (Primary)
  • Indications Thromboembolism
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 19 Jan 2007 Status changed from recruiting
    • 22 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top